Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
The proposed study is an open-label, single arm phase II study of venetoclax in combination
with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma.
The primary objective of the trial is to determine whether the combination of venetoclax with
rituximab in this patient population yields a clinically acceptable proportion of overall
responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins